However, when we simulated a wider range of the parameters that govern FGFR3 impact on proliferation and survival, we saw that for realistic values of α2 and γT, anti-FGFR3 therapy can not only have a substantial impact on tumor reductionbut targeted therapy can actually outperform anti-PD-L1 monotherapy. The gene discussed is CD274; the disease is neoplasm.